Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS-553 in relapsed/refractory CLL/SLL
NCT06979076Phase 2Not yet recruiting
- Sponsor
- MingSight Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
01
Overview
Phase 2 trial of MS-553 in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by MingSight Pharmaceuticals. Primary endpoints: Adverse Events at 2 years, Serious Adverse Events at 2 years and 4 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
MS-553
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06979076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979076.